Lukasz Jarzyna

Lukasz Jarzyna is the Vice President and Head of Bone, Metabolism, and Rare Cancers Global Marketing at Alexion Pharmaceuticals, Inc. He has a diverse background that combines a passion for healthcare and economics. Originally from Poland, Jarzyna aspired to be a doctor and work on HIV cures during his teenage years, influenced by his parents' involvement with an AIDS foundation. However, he ultimately pursued a degree in economics and began his career as a tax and accounting consultant in Vienna, Austria, where he started working with biopharma clients, including Amgen.

Jarzyna joined Amgen in Vienna, focusing on business planning and analysis, before moving to Zug, Switzerland. In 2015, he transitioned to Alexion Pharmaceuticals, initially working in strategic planning. He later became the head of global value, access, and pricing, where he has made significant contributions to the company's approach to drug pricing and access, particularly in the realm of rare diseases. His work has included developing sustainable pricing strategies and innovative access agreements to improve patient access to treatments like Ultomiris (ravulizumab) for paroxysmal nocturnal hemoglobinuria (PNH) .12

Jarzyna's commitment to addressing drug access delays is driven by his personal experiences and a strong sense of responsibility to improve the healthcare landscape, especially for patients with rare diseases. He emphasizes the importance of collaboration with stakeholders to expedite access to medicines, aiming to reduce the average time patients wait for treatment after regulatory approval .1